This case illustrates persistent anti-TNF-associated immune deviation and supports targeted IL-5 receptor blockade as an effective strategy for refractory eosinophilic gastrointestinal disease while maintaining CD remission. This evidence concerns the gene TNF and eosinophilic gastrointestinal disease.